← All Immatics NV filings

Immatics NV 20-F annual reports

The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.

NASDAQ
IMTX
Immatics NV
20-F: Immatics Advances PRAME Therapies, Secures Funding
Immatics N.V. reports significant progress in its PRAME-directed immunotherapy pipeline, including advancing lead cell therapy anzu-cel into Phase 3, alongside a recent $107.2 million public offering.
NASDAQ
IMTX
Immatics NV
20-F: Immatics N.V. Files 2024 Annual Report, Highlights Clinical Progress and Financial Position
Immatics N.V. reports its 2024 financial results and provides an update on its clinical development programs, showcasing progress in TCR-based immunotherapies.
NASDAQ
IMTX
Immatics NV
20-F: Immatics N.V. Files 2023 Annual Report, Highlights Progress in TCR-Based Immunotherapy
Immatics N.V. released its 2023 annual report, detailing financial results and advancements in its T cell receptor (TCR)-based immunotherapy programs for solid tumors.